The synthetic biology market is on track to more than double to $56.48 billion by 2031, with genome engineering technologies like CRISPR-Cas9 and base editing driving over a third of the sector's value. According to Mordor Intelligence, the market's 19.14% CAGR from 2026 to 2031 underscores a shift from research tools to therapeutic and industrial applications, particularly in cell therapies and sustainable manufacturing.
Asia-Pacific's Growth Engine
Asia-Pacific is set to outpace North America and Europe, fueled by government initiatives in China, Japan, and South Korea aimed at biotech self-sufficiency. China's '14th Five-Year Plan' allocates billions to synthetic biology, while companies like BGI Group and GenScript are scaling CRISPR reagent production. This regional surge contrasts with slower growth in mature markets, where regulatory hurdles and high costs constrain expansion.
Genome engineering isn't just a tool—it's becoming the backbone of next-gen biologics and cell therapies, with Asia-Pacific investing heavily to capture market share.
Investor Implications
For investors, the growth signals opportunities beyond pure-play CRISPR firms. Companies like Ginkgo Bioworks (DNA) and Twist Bioscience (TWST) are leveraging synthetic biology for drug discovery and DNA synthesis, while agri-biotech players like Benson Hill use genome editing for crop optimization. However, risks include intellectual property disputes, as seen in the ongoing CRISPR patent battles, and regulatory uncertainty in emerging markets.
The competitive landscape is fragmenting, with startups like Sana Biotechnology and Caribou Biosciences advancing allogeneic cell therapies, while giants like Roche and Novartis acquire synthetic biology assets for pipeline diversification. As the market matures, consolidation is likely, with M&A activity focusing on platforms that enable scalable, cost-effective production of engineered organisms and therapies.
